AKBA FY 2021 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$212M-28.2% YoY

Gross Profit

$130M61.5% margin

Operating Income

-$265M-125.0% margin

Net Income

-$282M-133.3% margin

EPS (Diluted)

$-1.48

Cash Flow

Operating Cash Flow

-$253M

Free Cash Flow

-$253M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$529M

Total Liabilities

$455M

Stockholders' Equity

$74M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$212M	$295M	-28.2%
Gross Profit	$130M	$231M	-43.6%
Operating Income	-$265M	-$378M	+30.0%
Net Income	-$282M	-$385M	+26.7%